FDA Expands Use of Durvalumab to Non–small Cell Lung Cancer
The U.S. Food and Drug Administration (FDA) recently approved expanding the use of the immunotherapeutic durvalumab (Imfinzi) to include...
The U.S. Food and Drug Administration (FDA) recently approved expanding the use of the immunotherapeutic durvalumab (Imfinzi) to include...
A diverse group of about 220 physicians, patient advocates, and scientists in basic, translational, and clinical lung cancer research...
Cigarette smoking is the leading cause of death from lung cancer in the United States. That’s why November, Lung...
Last week, a flurry of U.S. Food and Drug Administration (FDA) oncology approvals concluded with the approval of the...
Earlier this week, the U.S. Food and Drug Association (FDA) announced it had approved the immunotherapeutic atezolizumab (Tecentriq) for...
Cancer Today Senior Editor Marci A. Landsmann shares her experience reporting on a young lung cancer survivor, Emily Bennett...
Dr. Patricia LoRusso works to find innovative therapeutics to reduce the toll of cancer on patients and their families.
On June 1, the U.S. Food and Drug Administration (FDA) approved a liquid biopsy test, a companion diagnostic test...
The U.S. Food and Drug Administration (FDA) recently approved the use of molecularly targeted therapeutic afatinib (Gilotrif) for treating...
A recent study in the AACR’s journal Cancer Epidemiology, Biomarkers & Prevention found an association between glycemic index (a...